CompletedNCT03605849
What is this study about?Researchers studied Centanafadine SR, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
This study has finished and is no longer accepting participants.
In Culver CityADHDMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT03605836
Official study titleA Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
In OrlandoADHDMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Enrolling By InvitationNCT07675538
Official study titleHigh-intensity Training for Adults With ADHD in Specialised Mental Health Care: A Mixed Methods Feasibility Study
This study is by invitation only.
In BergenADHDBehavioural studyAges 18+
- Countries
- Norway
- Sponsor
- Solli Distriktspsykiatriske Senter
CompletedNCT01369459
Official study titleFamily-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD
This study has finished and is no longer accepting participants.
In New YorkADHDBehavioural studyAges 13–17
- Countries
- United States
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
CompletedNCT06064942
Official study titleMultiple Family Narrative Therapy as Treatment for Chinese Families of Children With Attention-Deficit/Hyperactivity Disorder: A Randomised Controlled Trial
This study has finished and is no longer accepting participants.
In Hong KongADHDBehavioural studyAges 7–13
- Countries
- China
- Sponsor
- Hong Kong Baptist University
RecruitingACTRN12624001116516
Official study titleEvaluating the effect of the Tracking Cube on identification of neurodevelopmental concerns in primary healthcare
In AustraliaADHDInterventional studyAges 0 months+
- Countries
- Australia
- Sponsor
- Griffith University
Not Yet RecruitingACTRN12619001405101
Official study titleFeasibility of the AllPlay Learn professional development course for early childhood educators and primary school teachers: a pilot randomised controlled trial
This study isn't recruiting yet.
In AustraliaADHD, AnxietyInterventional studyAges 17–70
- Countries
- Australia
- Sponsor
- Deakin University
Not Yet RecruitingACTRN12621000715875
This study isn't recruiting yet.
In New ZealandADHDInterventional studyAges 16+
- Countries
- New Zealand
- Sponsor
- Auckland District Health Board
Not Yet RecruitingACTRN12622000162718
Official study titleMicronutrients and emotion dysregulation in children 5-10 years of age: a two-arm withdrawal single-case design
This study isn't recruiting yet.
In New ZealandADHDInterventional studyAges 5–10
- Countries
- New Zealand
- Sponsor
- University of Canterbury
Not Yet RecruitingACTRN12616000576426
Official study titleThe development, implementation and evaluation of FIT for PLAY: A Fundamental Integrative Training program, for Physically Literate and Active Youth with a mental health disorder
This study isn't recruiting yet.
In AustraliaADHD, AnxietyInterventional studyAges 6–12
- Countries
- Australia
- Sponsor
- Kathryn Fortnum
CompletedNCT02683265
What is this study about?Researchers compared Aptensio XR and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including Las VegasADHDMedication studyAges 4–6
- Countries
- United States
- Sponsor
- Rhodes Pharmaceuticals, L.P.
CompletedNCT02811211
Official study titleA Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
In WilmingtonADHDObservational studyAges 6–17
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company